Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Matthew G. Davenport"'
Autor:
Jason T. Ladner, Brett Beitzel, Patrick S. G. Chain, Matthew G. Davenport, Eric Donaldson, Matthew Frieman, Jeffrey Kugelman, Jens H. Kuhn, Jules O’Rear, Pardis C. Sabeti, David E. Wentworth, Michael R. Wiley, Guo-Yun Yu, Shanmuga Sozhamannan, Christopher Bradburne, Gustavo Palacios
Publikováno v:
mBio, Vol 5, Iss 3 (2014)
ABSTRACT Thanks to high-throughput sequencing technologies, genome sequencing has become a common component in nearly all aspects of viral research; thus, we are experiencing an explosion in both the number of available genome sequences and the numbe
Externí odkaz:
https://doaj.org/article/4dd7e67cfafd4f7da255f86e67a2e10e
Publikováno v:
Journal of Virology. 78:3542-3552
The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) is a key gene expressed in EBV type III latent infection that can transactivate numerous promoters, including those for all the other type III viral latency genes as well as cellular genes respo
Autor:
Jules O'Rear, David E. Wentworth, Patrick S. G. Chain, Brett Beitzel, Matthew G Davenport, Christopher E. Bradburne, Shanmuga Sozhamannan, Eric F. Donaldson, Pardis C. Sabeti, Michael R. Wiley, Matthew B. Frieman, Jens H. Kuhn, Jeffrey R. Kugelman, Gustavo Palacios, Jason T. Ladner, Guo-Yun Yu
Publikováno v:
mBio
mBio, Vol 5, Iss 3 (2014)
mBio, Vol 5, Iss 3 (2014)
Thanks to high-throughput sequencing technologies, genome sequencing has become a common component in nearly all aspects of viral research; thus, we are experiencing an explosion in both the number of available genome sequences and the number of inst
Autor:
Matthew G. Davenport, Joseph S. Pagano
Publikováno v:
Journal of Virology. 73:3154-3161
Expression of EBNA-1 protein is required for the establishment and maintenance of the Epstein-Barr virus (EBV) genome during latent infection. During type I latency, the Bam HI Q promoter (Qp) gives rise to EBNA-1 expression. The dominant regulatory
Publikováno v:
Journal of AOAC International. 94(4)
Standards and third-party testing are necessary to demonstrate the performance and limitations of biological threat agent (biothreat) detection technologies to allow appropriate response actions by end-users and responders. In order to address this n